Navigation Links
Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
Date:9/17/2007

FREMONT, Calif., Sept. 17 /PRNewswire-FirstCall/ -- Vermillion, Inc. (the "Company") (Nasdaq: VRML) announced today that it received written notification from The Nasdaq Stock Market ("Nasdaq") that the Company has regained compliance with Nasdaq Marketplace Rule 4310(c)(3) as a result of achieving a market value of listed securities of the Company's common stock of $35 million or more for a period of 10 consecutive business days. Nasdaq notified the Company on August 17, 2007 that the Company was not in compliance with the minimum requirements set forth in Marketplace Rule 4310(c)(3), which requires that a company listed on Nasdaq have a minimum of $2.5 million stockholders' equity, $35 million market value of listed securities or $500,000 of net income from continuing operations. According to the Nasdaq, this matter is now closed.

This notification, however, does not resolve the noncompliance with Marketplace Rule 4310(c)(4) pertaining to the minimum bid price requirement for continued listing. Pursuant to notice from Nasdaq dated September 6, 2007, the Company has a period of 180 calendar days, or until March 4, 2008, to regain compliance with this Rule.

About Vermillion

Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has ongoing diagnostic programs in oncology/hematology, cardiology and women's health with an initial focus in ovarian cancer. Based in Fremont, California, more information about Vermillion can be found on the Web at

SOURCE Vermillion, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... LEXINGTON, Mass. , April 21, 2015 ... company developing transformative pharmaceutical products for subcutaneous ... its pivotal trial of its investigational proprietary ... treatment of edema associated with congestive heart ... development, scPharmaceuticals is developing a proprietary patch ...
(Date:4/21/2015)... Cleveleys (UK) (PRWEB) April 21, 2015 ... technology and its clinical applications will be ... Participants include engineers, scientists, regulators and clinicians ... The meeting is sponsored by Invibio Biomaterial ... polymer-based biomaterials, a specialist in manufacturing and ...
(Date:4/20/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the ... commercializing proven cancer therapies in new orphan drug ... 106th Annual Meeting of the American Association ... the potential for its lead product candidate ...
(Date:4/20/2015)... 20, 2015  Eli Lilly and Company (NYSE: ... targeted cancer therapies, reflecting Lilly,s diverse oncology pipeline, during ... 2015, held April 18-22 in Philadelphia ... Patients" is the theme of this year,s AACR meeting ... broadening its portfolio of therapies that accelerate the pace ...
Breaking Biology Technology:scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 32nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 22nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 2Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 6
... Fewer ... Patients Than Originally Planned, SEATTLE, Sept. 6 Cell ... that following,discussions with the U.S. Food and Drug Administration (FDA) ... the Company has decided to conduct a full analysis of ...
... relatively new to the market, liquid crystal display (LCD) ... technique created by University of Houston professors., Vincent Donnelly, ... College of Engineering, have developed a technique that allows ... television industry away from the LCD display to the ...
... ThermoGenesis,Corp. (Nasdaq: KOOL ), a leading supplier ... administer therapeutic doses of,adult stem cells for treatment of ... for the fourth quarter and full year ended,June 30, ... Call and Webcast Management will host a conference ...
Cached Biology Technology:Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission 2Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission 3Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission 4New technique producing small things in large quantities 2ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007 2ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007 3
(Date:4/20/2015)... Calif. , April 20, 2015 Huntington ... Gabriel Valley to implant a new miniaturized, wireless monitoring ... System is the first and only FDA-approved heart failure ... hospital admissions when used by physicians to manage heart ... sensor that is implanted in the pulmonary artery (PA) ...
(Date:4/20/2015)... , April 20, 2015 ...   Glenbeigh Records Management (GRM), Ireland,s ... with Dubai Islamic Bank. Having built up an impressive track ... now a leading player within the records management sector in ... expects to double is GCC staffbase and employ a further ...
(Date:4/17/2015)... BURNABY, Canada , April 17, 2015 /PRNewswire/ ... projects, growing security concerns, and technological advancement to ... Arabia until 2020   ... " Saudi Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric ... is projected to register growth at CAGR ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... Laboratory for Nanophotonics (LANP) have unveiled the "nanoegg," ... particles. A cousin of the versatile nanoshell, nanoeggs ... properties can be harnessed for molecular imaging, medical ... described in the July 18 issue of the ...
... of Minnesota researchers have discovered how a prevalent fungal ... United States overcomes the effects of antifungal drugs by ... , Candida albicans, a type of yeast present in ... healthy people, it can cause mild oral and vaginal ...
... Medicine have taken a first step toward growing blood ... into living organisms. , Starting with embryonic stem cells ... colleagues have successfully differentiated the stem cells into myocytes, ... placing them in a life-like growth environment that the ...
Cached Biology News:Rice scientists unveil 'nanoegg' 2U of M researchers discover genetic key to treating deadly fungal infections 2Stanford doctors advance in bid to turn mice stem cells into blood vessels 2Stanford doctors advance in bid to turn mice stem cells into blood vessels 3
... separation and fractionation of nucleic-acid ... nuclei from cytosolic proteins A ... greatly facilitating study of low-abundance ... acid binding proteins (e.g., transcription ...
... of Ham's F-12 was developed for culturing ... fusion. The modification consists of doubling the ... acid. The salt concentrations have been altered ... zinc sulfate per liter, which may render ...
... whose sequence corresponds to residues 1-18 from rat rab 3D. ... - A - S - A - S - E - ... - D - A - A - D - Q - ... control experiments with the polyclonal antibody that reacts with this product ...
... Bisulfite Kit enables complete conversion of ... than 6 hours. The highly sensitive ... DNA degradation and a spin-column-based purification ... and reliable results for all downstream ...
Biology Products: